Olmesartán Sandoz (Olmesartan Medoxomil)

Olmesartan Medoxomil is an ARB indicated for the management of hypertension and related cardiovascular conditions.

• Essential hypertension: lowers systolic and diastolic blood pressure in adults with primary hypertension.
• Hypertension with cardiovascular risk: contributes to blood pressure control, reducing strain on the heart and vessels.
• Hypertension in elderly patients: provides effective blood pressure reduction with a favorable tolerability profile.

• Olmesartan Medoxomil is a selective antagonist of the angiotensin II type 1 (AT1) receptor. By blocking AT1, it prevents angiotensin II‑mediated vasoconstriction and aldosterone secretion, leading to vasodilation, reduced sodium and water retention, and ultimately a decrease in systemic blood pressure.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate pain in the head region.
• Fatigue: feeling unusually tired or weak.
• Abdominal pain: discomfort or cramps in the stomach area.
• Cough: occasional dry throat irritation.
• Hyperkalemia (mild): slight increase in blood potassium levels.

Serious or Rare Side Effects

• Angioedema: swelling of the face, lips, tongue, or throat that may impair breathing.
• Severe hyperkalemia: marked elevation of potassium that can affect heart rhythm.
• Acute renal impairment: sudden decline in kidney function.
• Hypotension: significant drop in blood pressure causing faintness.
• Hepatic injury: abnormal liver enzyme elevations.
• Neutropenia: reduced neutrophil count increasing infection risk.

Patients should be monitored for safety and appropriate use.

• Monitor blood pressure: ensure therapeutic targets are achieved without excessive lowering.
• Assess renal function: check serum creatinine and eGFR before and during therapy.
• Check electrolytes: especially potassium levels to avoid hyperkalemia.
• Use caution in hepatic impairment: dose adjustment may be required.
• Avoid in pregnancy: potential fetal harm; discontinue if pregnancy is confirmed.
• Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Olmesartan may interact with several drug classes.

Major Interactions (Avoid)

• Aliskiren (in diabetes): combined use can increase risk of renal dysfunction.
• Potassium‑sparing diuretics: may cause dangerous hyperkalemia.
• ACE inhibitors: concurrent use raises hyperkalemia and renal impairment risk.
• Lithium: increased lithium levels leading to toxicity.
• NSAIDs (high dose): may blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely)

• Thiazide diuretics: may enhance hypotensive effect.
• CYP3A4 inhibitors (e.g., ketoconazole): can raise olmesartan plasma concentrations.
• NSAIDs (regular use): monitor renal function and blood pressure.
• Antidiabetic agents: blood glucose may improve, requiring dose adjustment.
• Rifampin: may reduce olmesartan effectiveness by increasing metabolism.